Gabapentin controlled release - Labopharm

Drug Profile

Gabapentin controlled release - Labopharm

Alternative Names: DDS 2003; Gabapentin sustained release - Labopharm

Latest Information Update: 10 Oct 2011

Price : $50

At a glance

  • Originator Labopharm
  • Class Amines; Aminobutyric acids; Analgesics; Antiepileptic drugs; Antimanics; Antiparkinsonians; Anxiolytics; Cyclohexanecarboxylic acids; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Epilepsy; Neuralgia

Most Recent Events

  • 13 May 2004 Preclinical trials in Neuralgia in Canada (unspecified route)
  • 13 May 2004 Preclinical trials in Epilepsy in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top